



COVID-19 vaccination algorithm for people without immunocompromise, ages 6 months–4 years, mRNA vaccines April 2023*




*To see product-specific doses and intervals of administration, see Table 1 and 2 forthcoming in Interim Clinical Considerations, forthcoming.

COVID-19 vaccination algorithm for people without immunocompromise, age 5 years, mRNA vaccines April 2023*



*To see product-specific doses and intervals of administration, see reference Table 1 in Interim Clinical Considerations, forthcoming

COVID-19 vaccination algorithm for people who are NOT moderately or severely immunocompromised, age 6 years and older, mRNA vaccines April 2023*



*To see product-specific doses and intervals of administration, see reference Table 1 in Interim Clinical Considerations, forthcoming.

**People ages 65+ have the option to receive 1 additional bivalent mRNA dose at least 4 months after the first dose of a bivalent mRNA vaccine.

Table 1. COVID-19 vaccination schedule for people who are NOT moderately or severely immunocompromised by COVID-19 vaccination history, April 2023: Ages 6 months–4 years

COVID-19 vaccination history	Bivalent vaccine	Number of bivalent doses indicated	Dosage (mL/ug)	Vaccine vial cap and label colors	Interval between doses
Unvaccinated	Moderna or	2	0.25 mL/25 ug	Dark blue cap; gray label border	Dose 1 and Dose 2: 4–8 weeks
	Pfizer BioNTech	3	0.2 mL/3 ug	Maroon	Dose 1 and Dose 2: 3–8 weeks Dose 2 and dose 3: At least 8 weeks
1 dose monovalent Moderna	Moderna	1	0.25 mL/25 ug	Dark blue cap; gray label border	4-8 weeks after monovalent dose
2 doses monovalent Moderna	Moderna	1	0.2 mL/10 ug	Dark pink cap; yellow label border	At least 8 weeks after last monovalent dose
2 doses monovalent Moderna and 1 dose bivalent Moderna	NA; previously received 1 bivalent vaccine dose	NA	NA	NA	NA
1 dose monovalent Pfizer-BioNTech	Pfizer BioNTech	2	0.2 mL/3 ug	Maroon	Dose 1: 3–8 weeks after monovalent dose Dose 1 and Dose 2: At least 8 weeks
2 doses monovalent Pfizer-BioNTech	Pfizer BioNTech	1	0.2 mL/3 ug	Maroon	At least 8 weeks after last monovalent dose
3 doses monovalent Pfizer-BioNTech	Pfizer BioNTech	1	0.2 mL/3 ug	Maroon	At least 8 weeks after last monovalent dose
2 doses monovalent Pfizer-BioNTech and 1 dose bivalent Pfizer-BioNTech	NA; previously received 1 bivalent vaccine dose	NA	NA	NA	NA

Table 1. COVID-19 vaccination schedule for people who are NOT moderately or severely immunocompromised by COVID-19 vaccination history, April 2023: Age 5 years

COVID-19 vaccination history	Bivalent vaccine	Number of bivalent doses indicated	Dosage (mL/ug)	Vaccine vial cap and label colors	Interval between doses
Unvaccinated	Moderna ___or___	2	0.25 mL/25 ug	Dark blue cap; gray label border	Dose 1 and Dose 2: 4–8 weeks
	Pfizer BioNTech	1	0.2 mL/10 ug	Orange	
1 dose monovalent Moderna	Moderna ___or___	1	0.25 mL/25 ug	Dark blue cap; gray label border	4–8 weeks after monovalent dose
	Pfizer BioNTech	1	0.2 mL/10 ug	Orange	At least 8 weeks after monovalent dose
2 doses monovalent Moderna	Moderna ___or___	1	0.2 mL/10 ug	Dark pink cap; yellow label border	At least 8 weeks after last monovalent dose
	Pfizer BioNTech	1	0.2 mL/10 ug	Orange	At least 8 weeks after last monovalent dose
2 doses monovalent Moderna and 1 dose bivalent mRNA	NA; previously received 1 bivalent vaccine dose	NA	NA	NA	NA
1 or more doses monovalent Pfizer-BioNTech	Pfizer-BioNTech	1	0.2 mL/10 ug	Orange	At least 8 weeks after last monovalent dose
2 doses monovalent Pfizer-BioNTech and 1 dose bivalent Pfizer-BioNTech	NA; previously received 1 bivalent vaccine dose	NA	NA	NA	NA

